Lilly’s neuroscience head Anne White to retire after 30-year career

INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY), a pharmaceutical giant with a market capitalization of $629.72 billion and impressive revenue growth of 36.83% over the last twelve months, announced Wednesday that Anne White, executive vice president and president of Lilly Neuroscience, will retire effective December 31, 2025, after 30 years with the company.

White will continue in her current role and remain on Lilly’s Executive Committee until her retirement date. The company has begun an internal and external search for her successor. According to InvestingPro, Lilly maintains a strong financial health score, with 11 analysts recently revising their earnings estimates upward for the upcoming period.

During her tenure, White oversaw the development and launch of multiple medicines, including Lilly’s first Alzheimer’s treatment. She previously led Lilly Oncology, where she played a key role in developing the late-stage portfolio and the acquisition of Loxo Oncology.

"Anne’s career has been defined by a deep commitment to advancing medicines for some of the most challenging diseases affecting patients globally," said David A. Ricks, Lilly’s chair and CEO, in a press release statement.

White’s leadership helped expand Lilly’s neuroscience portfolio to include new medicines in neurodegeneration, pain, substance use disorders, and psychiatry. She also led efforts to reduce drug development timelines across the pipeline.

Recognized for her advocacy for inclusion, White serves on the board of Lambda Legal and has been named one of the Most Influential Women Executives in Corporate America by WomenInc. The Indianapolis Business Journal has also recognized her as a Woman of Influence in Indianapolis.

Lilly, founded nearly 150 years ago, develops medicines across therapeutic areas including diabetes, obesity, Alzheimer’s disease, immune system disorders, and cancer. The company has maintained dividend payments for 55 consecutive years, with a recent dividend growth of 15.38%. InvestingPro analysis shows the company’s robust financial position, with detailed metrics and insights available in the comprehensive Pro Research Report, part of the coverage of 1,400+ top US stocks.

In other recent news, Eli Lilly has raised the price of its weight loss drug Mounjaro in the United Kingdom by up to 170%, according to a report by the Financial Times. The price for a month’s supply of the highest doses will increase from £122 to £330. Additionally, Cantor Fitzgerald has lowered its price target for Eli Lilly to $825 from $975, maintaining an Overweight rating due to concerns over the company’s oral weight loss drug candidate, orforglipron, which did not meet market expectations. Guggenheim also reduced its price target for Eli Lilly to $875 from $942, despite the company surpassing second-quarter earnings expectations and raising its full-year guidance.

Meanwhile, Viking Therapeutics has received positive attention from analysts following the release of Phase 2 VENTURE-Oral trial data. Truist Securities reiterated a Buy rating and set a price target of $75, citing favorable weight loss results from the trial. The trial showed placebo-adjusted weight loss of up to 10.9% for the highest dose of the oral VK2735. JPMorgan also maintained an Overweight rating on Viking Therapeutics, noting the strong weight loss results of up to 11% for the highest dosing arms in the trial. These developments highlight significant activity in the pharmaceutical sector concerning weight loss treatments.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.